Remibrutinib Around Procedures: What the Data Mean for Practice

How should clinicians weigh reassuring trial findings against prescribing guidance that recommends interrupting remibrutinib around surgery? Continuing the REMIX-1/-2 analysis, Nicholas Brownstone, MD, considers where the evidence offers some reassurance and where clinical judgment remains essential. Procedural bleeding risk is only part of the picture; concomitant anticoagulant use, bleeding history, and the severity of a patient's CSU may also influence treatment planning. Dr Brownstone discusses his approach to balancing these considerations, counseling patients, and coordinating with proceduralists, with particular attention to what dermatology PAs and NPs should flag, document, and coordinate before and after a procedure.